Study highlights potential benefits of GSK heart drug

A way of fighting heart disease being pioneered by GlaxoSmithKline (NYSE: GSK) got a boost today from a scientific study that appears in The Lancet stressed the significance of an artery-clogging enzyme. The study suggests that the enzyme, Lp-PLA2, plays as much of a role in the risk of heart disease as high blood pressure and bad cholesterol. "Lp-PLA2 activity and mass each show continuous associations with risk of coronary heart disease, similar in magnitude to that with non-HDL...